【摘要】：目的對(duì)比不同抗病毒治療方案針對(duì)不同時(shí)期慢性乙型肝炎的臨床療效,尋找乙型肝炎治療的更優(yōu)方案,提高治療水平。方法收集2010年6月-2013年12月收治的108例慢性乙型肝炎患者臨床資料,依據(jù)慢性乙型肝炎分期標(biāo)準(zhǔn)分為免疫清除期54例患者作為觀察組,免疫耐受期54例患者作為對(duì)照組,分別采用干擾素-α法、恩替卡韋法及聯(lián)合治療3種不同的抗病毒治療方法,療程均為48周;觀察兩組患者采用3種方法治療后肝功能、HBV-DNA定量及乙型肝炎病毒血清標(biāo)志物等指標(biāo),對(duì)比3種方法的治療效果,采用SPSS15.0軟件進(jìn)行統(tǒng)計(jì)分析。結(jié)果 3種方法治療后24、48周觀察組患者血清HBV-DNA水平、門(mén)冬氨酸氨基轉(zhuǎn)移酶、丙氨酸氨基轉(zhuǎn)移酶、總膽紅素水平均低于對(duì)照組(P0.05);聯(lián)合治療方法治療后48周觀察組患者肝功復(fù)常率及HBV-DNA、HBeAg轉(zhuǎn)陰率均優(yōu)于兩種單獨(dú)的治療方案(P0.05)。結(jié)論免疫清除期是接受治療的重要時(shí)期,藥物恩替卡韋和干擾素聯(lián)合使用治療慢性乙型肝炎的效果明顯優(yōu)于單獨(dú)一種抗病毒藥物的治療,同時(shí)可以避免出現(xiàn)耐藥性,因此選擇免疫清除期采用聯(lián)合給藥方法有利于慢性乙型肝炎的治療。
[Abstract]:Objective to compare the clinical efficacy of different antiviral therapy for chronic hepatitis B in different periods, and to find a better treatment for hepatitis B and to improve the treatment level. Methods the clinical data of 108 patients with chronic hepatitis B were collected from June 2010 to December 2013. According to the staging criteria of chronic hepatitis B, 54 patients with immune clearance were divided into observation group and 54 patients with immune tolerance as control group. Interferon-偽 method, entecavir method and combined therapy were used for 48 weeks, respectively. The serum markers of hepatitis B virus and HBV-DNA of liver function were measured. To compare the therapeutic effects of the three methods, SPSS15.0 software was used for statistical analysis. Results the serum levels of HBV-DNA, aspartate aminotransferase, alanine aminotransferase, and alanine aminotransferase were measured in the observation group after 24 weeks of treatment. Total bilirubin levels were lower than the control group (P0.05); the observation group 48 weeks after the treatment of liver function recovery rate and HBV-DNA,HBeAg negative rate were better than the two treatment alone (P0.05). Conclusion Immunoclearance is an important period of treatment. The efficacy of combined use of entecavir and interferon in the treatment of chronic hepatitis B is better than that in the treatment of chronic hepatitis B with a single antiviral drug, and drug resistance can be avoided at the same time. Therefore, the combined administration of immunoclearance is beneficial to the treatment of chronic hepatitis B.
【作者單位】： 浙江省平陽(yáng)縣人民醫(yī)院感染科;
【基金】：浙江省衛(wèi)生廳規(guī)劃基金資助項(xiàng)目(ZW-2010B-027)
【分類(lèi)號(hào)】：R512.62

【參考文獻(xiàn)】

相關(guān)期刊論文 前2條

1 金友國(guó);;慢性乙型病毒性肝炎的抗病毒治療進(jìn)展[J];中國(guó)臨床藥學(xué)雜志;2011年02期

2 薛闖;;39例慢性乙型肝炎抗病毒治療的臨床效果探討[J];中外醫(yī)療;2013年18期

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 于樂(lè)成;何長(zhǎng)倫;汪茂榮;;HBsAg定量與抗病毒治療關(guān)系的研究進(jìn)展[J];傳染病信息;2013年04期

2 姚偉明;徐東平;;抗HBV藥物靶位的研究進(jìn)展[J];傳染病信息;2013年06期

3 ;Chinese Consensus on Antiviral Treatment of Chronic Hepatits B Patients with Nucleos(t)ide Analogues[J];Infection International(Electronic Edition);2013年02期

4 夏國(guó)美;李旭;葉s，

本文編號(hào)：2254720